As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
The past six months have been a windfall for Corcept’s shareholders. The company’s stock price has jumped 201%, hitting $122.93 per share. This was partly du...
Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnin...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Lookin...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability
Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year t...
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. Corcept mi...
What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to '...
Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season. Lo...
